Form 4: Krystal Biotech Director Catherine Mazzacco Acquires 5,000 Stock Options
SEC Form 4 Filing
Catherine Mazzacco, a director at Krystal Biotech, Inc., acquired 5,000 stock options on June 30, 2024, vesting monthly over one year.
Summary
- Catherine Mazzacco, a director of Krystal Biotech, Inc., filed a Form 4 on July 1, 2024, reporting a transaction.
- On June 30, 2024, Mazzacco acquired 5,000 stock options with an exercise price of $183.64.
- These options vest in equal monthly installments over a one-year period and expire on June 30, 2034.
- Following the transaction, Mazzacco directly owns 5,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it shows a director's increased stake in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | Date of stock option grant and transaction. |
| 06/30/2034 | Expiration date of the stock options. |
| 07/01/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.